证券代码：300871 证券简称：回盛生物 公告编号：2025-096 武汉回盛生物科技股份有限公司 关于董事会换届选举完成及聘任高级管理人员、证券事务代表 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开 2025 年第三次临时股东大会，审议通过了《关于董事会换届暨选举 第四届董事会非独立董事的议案》《关于董事会换届暨选举第四届董事会独立 董事的议案》，选举产生了第四届董事会非职工代表董事，与公司职工代表大 会选举产生的第四届董事会职工代表董事周健女士，共同组成公司第四届董事 会。同日，公司召开第四届董事会第一次会议，选举产生了第四届董事会董事 长、各专门委员会委员，聘任了公司高级管理人员及证券事务代表。现将有关 情况公告如下： 一、第四届董事会及各专门委员会的组成情况 （一）第四届董事会的组成情况 非独立董事：张卫元先生（董事长）、刘泽祥先生 独立董事：冉明东先生、汪明先生 职工代表董事：周健女士 公司第四届董事会由 5 名董事组成，其中独立董事 2 名，职工代 ...

第四届董事会第一次会议决议公告 证券代码：300871 证券简称：回盛生物 公告编号：2025-095 武汉回盛生物科技股份有限公司 （一）审议通过了《关于选举第四届董事会董事长的议案》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《公司法》《公司章程》等有关规定，公司全体董事一致同意选举张 卫元先生担任公司第四届董事会董事长，任期三年，自本次董事会审议通过之 日起至第四届董事会任期届满之日止。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上披露的《关于董 事会换届选举完成及聘任高级管理人员、证券事务代表的公告》（公告编号： 1 2025-096）。 表决结果为：同意 5 票；反对 0 票；弃权 0 票。本议案获得通过。 一、董事会会议召开情况 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开的 2025 年第三次临时股东大会选举产生的第四届董事会非职工代表 董事，以及于 2025 年 9 月 28 日召开的 2025 年第一次职工代表大会选举产生 的第四届董事会职工代表董事，共同组成第四届 ...

Group 1 - The core viewpoint of the news is that Huisheng Biological has experienced fluctuations in its stock price and trading volume, with a significant increase in stock price year-to-date, but recent declines in the short term [1] - As of October 16, Huisheng Biological's stock price was 20.92 yuan per share, with a market capitalization of 4.233 billion yuan and a trading volume of 80.2648 million yuan [1] - The company has seen a net outflow of main funds amounting to 2.2558 million yuan, with large orders showing a mixed buying and selling pattern [1] Group 2 - Huisheng Biological operates primarily in the veterinary medicine sector, with 93.56% of its revenue coming from veterinary raw materials and formulations [1] - As of June 30, the number of shareholders increased by 65.21% to 23,500, while the average number of circulating shares per person decreased by 28.44% [2] - For the first half of 2025, Huisheng Biological reported a revenue of 822 million yuan, representing a year-on-year growth of 88.45%, and a net profit attributable to shareholders of 117 million yuan, up 325.88% year-on-year [2] Group 3 - Since its A-share listing, Huisheng Biological has distributed a total of 236 million yuan in dividends, with 135 million yuan distributed over the past three years [3]

Core Viewpoint - The company, Huisheng Biological (300871), is actively expanding its overseas market presence, primarily focusing on the export of raw materials, while its formulation business is still in the exploratory phase [2]. Group 1: Stock Performance - As of October 15, 2025, Huisheng Biological's stock closed at 21.35 yuan, an increase of 1.47%, with a turnover rate of 2.25%, a trading volume of 45,500 shares, and a transaction amount of 96.5641 million yuan [1]. Group 2: Investor Relations - The company has received inquiries regarding its competitiveness in overseas markets and its strategies for international expansion, indicating a positive trend in overseas sales [2]. - The company has not yet provided a third-quarter earnings forecast, with the report scheduled for release on October 28 [2]. - The company is awaiting approval from the China Securities Regulatory Commission for its targeted stock issuance, with the review inquiry response already submitted [2]. Group 3: Market Activity - On October 15, there was a net inflow of 1.2384 million yuan from major funds, suggesting increased short-term interest in Huisheng Biological [2]. - Retail investors showed a net outflow of 1.9195 million yuan, while speculative funds had a net inflow of 0.6811 million yuan [2].

Group 1 - The company is actively expanding its overseas market presence, with positive sales growth in its international business [2] - The primary component of the overseas business is the export of active pharmaceutical ingredients (APIs), while the formulation export business is still in the exploratory phase [2]

Core Viewpoint - The animal health sector experienced a decline of 0.68% on October 14, with Xianfeng Holdings leading the drop. The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1]. Stock Performance Summary - Zhongmu Co., Ltd. (600195) closed at 7.35, up 1.66% with a trading volume of 120,000 shares and a transaction value of 87.91 million yuan [1]. - Yongshun Biological (920729) closed at 9.31, up 0.54% with a trading volume of 13,800 shares and a transaction value of 12.82 million yuan [1]. - Biological Co. (600201) closed at 10.60, up 0.28% with a trading volume of 624,200 shares and a transaction value of 672 million yuan [1]. - Other notable stocks include Ruip Bio (300119) down 0.45% and Jinhai Bio (002688) down 0.98% [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 8.12 million yuan from institutional investors, while retail investors had a net inflow of 4.61 million yuan [2][3]. - Major stocks like Biological Co. (600201) experienced a net inflow of 62.91 million yuan from institutional investors, while Xianfeng Holdings (002141) saw a net outflow of 9.04 million yuan [3].

Core Insights - The animal health sector experienced a rise of 1.98% on October 10, with Bio-Pharmaceuticals leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Bio-Pharmaceuticals (600201) closed at 10.16, up 4.42% with a trading volume of 808,300 shares and a transaction value of 815 million [1] - Other notable performers included: - Houbang Holdings (002141) at 3.85, up 3.77% [1] - Ruipu Biological (300119) at 21.87, up 3.16% [1] - Dayu Biological (920970) at 66.6, up 2.62% [1] - Huisheng Biological (300871) at 21.33, up 2.06% [1] Capital Flow - The animal health sector saw a net inflow of 111 million from institutional investors, while retail investors experienced a net outflow of 96.24 million [2] - The capital flow for key stocks included: - Bio-Pharmaceuticals (600201) with a net inflow of 73.87 million from institutional investors [3] - Huisheng Biological (300871) with a net inflow of 17.64 million from institutional investors [3] - Houbang Holdings (002141) with a net inflow of 16.38 million from institutional investors [3]

Core Insights - The animal health sector experienced a slight increase of 0.01% on October 9, with the leading stock being Driveline [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Driveline (920275) closed at 9.57, up 1.38%, with a trading volume of 17,600 and a turnover of 11.63 million [1] - Jinhai Biological (002688) closed at 6.77, up 1.20%, with a trading volume of 183,400 and a turnover of 123 million [1] - Biological Shares (600201) closed at 9.73, up 0.93%, with a trading volume of 470,500 [1] - Huisheng Biological (300871) closed at 20.90, up 0.87%, with a trading volume of 41,600 [1] - Other notable stocks include Plai Ke (603566) at 13.82, up 0.58%, and Haili Biological (603718) at 6.81, up 0.15% [1] Capital Flow - The animal health sector saw a net outflow of 53.09 million from institutional investors, while retail investors had a net inflow of 28.12 million [2] - The total net inflow from speculative funds was 24.97 million [2] Individual Stock Capital Flow - Ruipu Biological (300119) had a net inflow of 7.31 million from institutional investors, while it experienced a net outflow of 9.14 million from retail investors [3] - Plai Ke (603566) saw a net inflow of 2.41 million from institutional investors but a net outflow of 6.28 million from retail investors [3] - Other stocks like *ST Green Kang (002868) and Jinhai Biological (002688) experienced significant net outflows from institutional investors [3]

Group 1 - The core point of the article is the announcement by Huisheng Biological regarding the composition of its fourth board of directors, which will consist of 5 members, including 2 non-independent directors, 2 independent directors, and 1 employee representative director [1] - The board has nominated Zhang Weiyuan and Liu Zexiang as candidates for non-independent directors, while Ran Mingdong and Wang Ming are nominated as candidates for independent directors [1]

Core Points - The company Huibei Huisheng Biotechnology Co., Ltd., a subsidiary of Huisheng Bio, has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its new veterinary drug "Yin Qiao Lan Qin Oral Solution" [1] Summary by Category - **Regulatory Approval** - The Ministry of Agriculture and Rural Affairs approved the joint application for the new veterinary drug [1] - The new veterinary drug registration certificate was issued on September 26, 2025 [1]